Printer Friendly

TELOR OPHTHALMIC PHARMACEUTICALS, INC. EXPANDS REGULATORY AFFAIRS GROUP; APPOINTS DIRECTOR, REGULATORY AFFAIRS AND COMPLIANCE OFFICER

TELOR OPHTHALMIC PHARMACEUTICALS, INC. EXPANDS REGULATORY AFFAIRS GROUP;
 APPOINTS DIRECTOR, REGULATORY AFFAIRS AND COMPLIANCE OFFICER
 WOBURN, Mass., Sept. 23 /PRNewswire/ -- Telor Ophthalmic Pharmaceuticals, Inc. today announced that it has appointed Edward J. Hiross, Ph.D., to director, regulatory affairs and Jeanne A. Russell to compliance officer.
 "The appointment of Dr. Hiross and Ms. Russell is a key step in building Telor's regulatory affairs group," said Stephen J. Riggi, Ph.D., president and chief executive officer of Telor. "Their considerable experience with regulatory and compliance issues will be an asset as our products continue to advance through clinical development." Earlier this year, Telor began clinical trials with its lead product , EY-105, for use in lowering intraocular pressure during eye surgery.
 Prior to joining Telor, Hiross served as director of Regulatory Affairs for the Anaquest Division of BOC, Inc. He has also served in that position for The Boots Company and Sterling Drug and worked in the regulatory departments of ICI Americas, Ayerest Laboratories and Pfizer. Hiross attended St. John's College in New York, where he earned a Ph.D. in Pharmaceutical Chemistry, an M.S. in Pharmaceutics, an M.B.A. in Management and a B.S. in Pharmacy. He also received a B.S. in Biology from Fordham College.
 Russell comes to Telor from Biogen, Inc., where she worked for eight years, holding various positions in the regulatory compliance area, most recently as senior compliance specialist, quality assurance. Prior to joining Biogen, she worked at Muro Pharmaceuticals as a quality control chemist and at Norwich-Eaton Pharmaceuticals as a documentation scientist. Russell received her J.D. from Suffolk University Law School and a B.S. in chemistry from Widener University in Chester, Pa.
 Telor Ophthalmic Pharmaceuticals, Inc. is developing innovative products for the treatment of age-related eye diseases. The company's initial products in development are for controlling intraocular pressure following surgery and in glaucoma, and for other diseases of the eye. Telor began operations in 1989 and has its headquarters in Woburn, Mass.
 -0- 9/23/92
 /CONTACT: Stephen J. Riggi, 617-937-0393, or Lynne H. Brum of Feinstein Partners, 617-577-8110, for Telor/ CO: Telor Ophthalmic Pharmaceuticals, Inc. ST: Massachusetts IN: MTC SU: PER


TM -- NE003 -- 2469 09/23/92 08:29 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Sep 23, 1992
Words:371
Previous Article:SHOPKO STORES REPORTS SECOND QUARTER EARNINGS INCREASE OF 18.1 PERCENT
Next Article:TJ SYSTEMS EXPANDS INTO ATLANTA MARKET
Topics:


Related Articles
FREDERICK H. GARBER JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC. AS VICE PRESIDENT OF MARKETING
WALTER P. RAHN II JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC.
WALTER P. RAHN II JOINS TELOR OPHTHALMIC PHARMACEUTICALS, INC.
TELOR OPHTHALMIC PHARMACEUTICALS, INC. ANNOUNCES THE APPOINTMENT OF SOPHANN IM, PH.D., TO MANAGER OF PHARMACEUTICAL DIVISION
MEDCO RESEARCH APPOINTS ANNE MCKAY DIRECTOR OF REGULATORY AFFAIRS

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters